Vedolizumab (VDZ), a gut-selective anti-integrin monoclonal antibody, was approved for the treatment of Crohn’s disease (CD) and ulcerative colitis (UC) in 2014. VDZ is reported to achieve maximal efficacy after several months of therapy. This real-world observational analysis describes effective prolonged treatment of CD and UC patients (pts) with VDZ who achieved initial clinical response.